BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Luvometinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Luvometinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07004075-7648@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Luvometinib: Phase 3 readout est. (NCT07004075)
DESCRIPTION:Luvometinib\, phase 3\, Glioma.\nStudy: FCN-159 Monotherapy Ver
 sus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Pa
 tients With BRAF Alteration\nEstimated primary completion: 30 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/luvometinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07004075
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07728201-7648@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Luvometinib: Phase 2 readout est. (NCT07728201)
DESCRIPTION:Luvometinib\, phase 2.\nStudy: Response-adapted Luvometinib Wit
 h or Without Cytarabine in Langerhans Cell Histiocytosis\nEstimated primar
 y completion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/luvometinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07728201
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708285-7648@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Luvometinib: Phase 1/2 readout est. (NCT07708285)
DESCRIPTION:Luvometinib\, phase 1/2.\nStudy: Luvometinib in Combination Wit
 h Serplulimab for NF2-Related Tumors\nEstimated primary completion: 31 Dec
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/luvometin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7708285
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562581-7648@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Luvometinib: Phase 2 readout est. (NCT07562581)
DESCRIPTION:Luvometinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC\
 nEstimated primary completion: June 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/luvometinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07562581
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024394-7648@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20290923
DTEND;VALUE=DATE:20290924
SUMMARY:Luvometinib: Phase 1/2 readout est. (NCT07024394)
DESCRIPTION:Luvometinib\, phase 1/2.\nStudy: Follow-up Study to Evaluate th
 e Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibro
 matosis Type 1\nEstimated primary completion: 23 September 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/luvometinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07024394
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371182-7648@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Luvometinib: Phase na readout est. (NCT07371182)
DESCRIPTION:Luvometinib\, phase na.\nStudy: Luvometinib in Pediatric SS-LCH
  With Special-site Single/Multifocal Bone Lesions\nEstimated primary compl
 etion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/luvometinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07371182
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431060-7648@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Luvometinib: Phase na readout est. (NCT07431060)
DESCRIPTION:Luvometinib\, phase na.\nStudy: Modified LCH-III Regimen With o
 r Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocyto
 sis\nEstimated primary completion: 31 December 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/luvometinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07431060
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07713745-7648@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20360601
DTEND;VALUE=DATE:20360602
SUMMARY:Luvometinib: Phase 2 readout est. (NCT07713745)
DESCRIPTION:Luvometinib\, phase 2.\nStudy: Platform Research for Innovative
  Medicines in NF2-SWN (PRIME-NF2)\nEstimated primary completion: 1 June 20
 36. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/luvometinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07713745
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
